ATE289808T1 - Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben - Google Patents

Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben

Info

Publication number
ATE289808T1
ATE289808T1 AT96927325T AT96927325T ATE289808T1 AT E289808 T1 ATE289808 T1 AT E289808T1 AT 96927325 T AT96927325 T AT 96927325T AT 96927325 T AT96927325 T AT 96927325T AT E289808 T1 ATE289808 T1 AT E289808T1
Authority
AT
Austria
Prior art keywords
pct
nicotinamide
caroteinoid
treatment
methods
Prior art date
Application number
AT96927325T
Other languages
English (en)
Inventor
Ronald W Pero
Original Assignee
Optigenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optigenex Inc filed Critical Optigenex Inc
Application granted granted Critical
Publication of ATE289808T1 publication Critical patent/ATE289808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96927325T 1995-08-14 1996-08-07 Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben ATE289808T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US231495P 1995-08-14 1995-08-14
PCT/US1996/012790 WO1997006790A1 (en) 1995-08-14 1996-08-07 Carotenoid-nicotinamide-zinc compositions and methods of treatment using same

Publications (1)

Publication Number Publication Date
ATE289808T1 true ATE289808T1 (de) 2005-03-15

Family

ID=21700204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927325T ATE289808T1 (de) 1995-08-14 1996-08-07 Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben

Country Status (10)

Country Link
US (1) US6020351A (de)
EP (1) EP0844873B1 (de)
JP (1) JPH11511167A (de)
AT (1) ATE289808T1 (de)
AU (1) AU715430B2 (de)
CA (1) CA2229135A1 (de)
DE (1) DE69634404T2 (de)
ES (1) ES2238695T3 (de)
RU (1) RU2172630C2 (de)
WO (1) WO1997006790A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287796B1 (en) * 1998-06-16 2001-09-11 Niadyne Inc Biochemical method to measure niacin status in a biological sample
DK1143954T3 (da) * 1998-12-01 2004-12-20 Univ Kentucky Res Found Anvendelse af nicotinsyrederivater til behandling af DNA-skade i hudceller
US7012086B1 (en) 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
US6660297B2 (en) * 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
PT1393277E (pt) 2001-05-21 2006-09-29 Alcon Inc Utilizacao de inibidores de nf-kb para tratar disturbios de olho seco
US20030099626A1 (en) * 2001-11-20 2003-05-29 Health Education Corporation Nutrient absorption enhancing compositions and methods
US6979468B1 (en) 2002-12-06 2005-12-27 Sirius Laboratories Oral composition and method for the treatment of inflammatory cutaneous disorders
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
WO2004071208A1 (en) * 2003-02-14 2004-08-26 Mars Uk Limited Skin composition
EP1684776A1 (de) * 2003-07-25 2006-08-02 Washington State University Research Foundation Natürlicher astaxanthin-extrakt verringert die dna oxidation
US20050287227A1 (en) * 2004-04-16 2005-12-29 Ronald Pero Supplement containing carotenoid, nicotinamide, zinc, water soluble extract of uncaria species and method of the same
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
US20060269616A1 (en) * 2005-05-26 2006-11-30 Suracell, Inc. Supplement composition and method of use for enhancement of DNA repair process
IL184575A0 (en) * 2007-07-12 2008-01-20 Lycored Ltd Synergistic combinations for treating hypertension
US20100215768A1 (en) * 2009-02-24 2010-08-26 Pero Ronald W Nutritional supplement
US8968801B1 (en) * 2011-09-14 2015-03-03 Cellhealth Technologies Ltd. Supplement composition for supporting DNA repair and method of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA882404B (en) * 1987-05-13 1988-09-29 Spectral Bioanalysis, Limited Growth-suppressing infusion medium,growth-suppressing cell culture medium and processes for the suppression of transformed cell growth
US5008295A (en) * 1987-07-30 1991-04-16 Lion Corporation Method inhibiting the growth of cancer cells
US5234698A (en) * 1988-07-05 1993-08-10 Fahim Mostafa S Intraprostatic injection of zinc ions for treatment of inflammatory conditions and benign and malignant tumors of the prostate
JP2782823B2 (ja) * 1989-08-21 1998-08-06 吉富製薬株式会社 ニコチン酸アミド化合物
JPH0381222A (ja) * 1989-08-22 1991-04-05 Yoshitomi Pharmaceut Ind Ltd 制癌剤
US5162369A (en) * 1990-07-06 1992-11-10 Brigham Young University Composition and method for enhancing the immune system in warm-blooded animals exhibiting symptoms of antigenic morbidity
JP3691054B2 (ja) * 1992-01-16 2005-08-31 ボード、オブ、リージェンツ、ザ、ユニバーシティー、オブ、テキサス、システム 癌の治療におけるカロチノイド類の処方及び用法
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
CA2089607C (en) * 1992-11-05 1997-11-04 Ranjit K. Chandra Nutritional supplement for the elderly
US5294606A (en) * 1992-11-24 1994-03-15 Reliv' International Inc. Isotonic energy composition and method to use same
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis

Also Published As

Publication number Publication date
DE69634404T2 (de) 2005-12-29
JPH11511167A (ja) 1999-09-28
EP0844873A1 (de) 1998-06-03
AU6718696A (en) 1997-03-12
ES2238695T3 (es) 2005-09-01
AU715430B2 (en) 2000-02-03
EP0844873B1 (de) 2005-03-02
US6020351A (en) 2000-02-01
DE69634404D1 (de) 2005-04-07
WO1997006790A1 (en) 1997-02-27
RU2172630C2 (ru) 2001-08-27
EP0844873A4 (de) 2000-08-23
CA2229135A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
ATE289808T1 (de) Caroteinoid-nicotinamid-zink zusammensetzungen und verfahren zur behandlung unter verwendung derselben
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
TR199901173T2 (xx) Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
AU4310097A (en) Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
FI972703A (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
DE69833937D1 (de) Verwendung von zinkhyaluronat gegen magengeschwür
GEP20043267B (en) Adenosine Receptor Antagonists, Methods of Making and Using the Same
CY2198B1 (en) 1-Aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
ATE232094T1 (de) Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe
BG105275A (en) Tan-1057 derivatives
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
YU55998A (en) Oral or implant pharmaceutical formulation with controlled release
DE69124382T3 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
DE59609482D1 (de) Anellierte beta-carboline
DE59809592D1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties